Page 1

BIOTECH SECURITY TOKEN INITIAL EXCHANGE OFFER (IEO)

ADVISED BY DR GORAN ANDO

EXPERIENCED TEAM

NETWORKED

PROOF OF CONCEPT Proof of Concept has already been achieved in the native therapeutic protein of interest. This is rarely the case in Biotech Discovery Projects. Through this, Banksia has an almost ‘unfair advantage’ in its pathway into the clinic and Human Clinical Trials .

1

A Tokenised Royalty Stream Offer like this is truely innovative, and stands to totally transform the global Biotech funding paradigm. Blockchain for the first time has made this kind of offer logistically possible, bringing Biotech investment to the people!

4

Banksia’s BaRA technology has been secured under a Provisional Patent. Freedom to Operate and Patentability studies were undertaken by a ‘top tier’ Patent Law Firm. Our IP Management Strategy will be a driving force in Product Development

BANKSIA SECURES THE RIGHTS TO COMMERCIALIZE A BIOLOGICAL GOLD MINE

FULLY OPERATIONAL BaRA Token sales steadily fund the development of the BaRA Rheumatoid Arthritis therapeutic. Development and Clinical Milestones drive the token value.

HARNESSING THE POWER OF NATURE

ROYALTIES 50% SALE

7.5%

OPPORTUNITY

!

100X

7.5%

50%

INCENTIVES

10% PROVIDERS

25% EMPLOYEES

ROYALTY DEAL STATS 25%

BaRA Tokens are listed on further exchanges with larger volumes. Marketing is ramped-up in parallell

6 STEP PLAN

LISTING

INCENTIVES

30 Million BaRA Tokens are allocated to ‘incentives’. Investment pre-listing to enable the ‘listing event’ is eligible to a substantial portion of this pool

WE ARE HERE

Banksia will initially list each BaRA Token at:

US$1.00

65% 50%

10%

AVE

LIKELY

Banksia lists (IEO) its BaRA Security tokens on a mid-tier exchange and undertakes marketing activities

FOUNDERS

The native form of Banksia’s therapeutic protein was found to be 10 to 100 times more effective at suppressing TNF in whole human blood than the ‘Big Three’ leading drugs currently on the market

In a scenario where Banksia took 10% of this market on only a 10% royalty rate, each BARA Token would have yielded approximately US$4.00 per Token in that year alone...

20%

RAMP-UP Banksia has tokenized 50% of its future royalty stream of it’s BaRA Product. The proceeds of the ‘on exchange sale’ of these tokens will be used to fund the development and clinical trials of BaRA, and company activities

The top earning Anti-TNFs Hunira, Remicade & Enbrel earned US$31.87 Billion in 2015

The Inflammation Market is expected to reach 8.5 Million people by 2023 (~2% of the world’s population).

INTELLECTUAL PROPERTY 3

US$31.9 BILLION 8.5 MILLION

The Rheumatoid Arthritis market is projected to be US$80.7 Billion by 2020

2

BLOCKCHAIN

65%

US$80.7 BILLION

The Large Pharmaceutical companies are stereotypically relationship focused when it comes to ‘deal doing’. Having efficient and direct access to the decision makers will be vital for Banksia to achieve its Royalty Deal objectives

Key and foundational patents for all the ‘Big Three’ Anti-TNF Drugs have or will expire in the near future, creating an opening for generics and new therapies such as Banksia’s Anti-TNF

IP EXPIRY

In February 2018, the Biotech Nektar achieved a staggering 65% Royalty Deal with Bristol Meyers Squibb (BMS). A comparable deal for Banksia would be game changing

Banksia BioPharm

Former Chairman of Novo Nordisk A/S and Founding Fellow of the American College of Rheumatology. A highly respected and networked individual in the Pharmaceutical industry. A critical factor in deal doing.

Over 50 years combined Biotech, Board and C-Suite experience. Proven fund raisers in both Listed and Start-up Biotech companies. A potent blend of business, scientific and creative minds.

COMPETITOR

PRELISTING Establish web presence social media and BaRA Token minting & Storage

GOAL

STRETCH NEKTAR GOAL DEAL

DISCOVERY BaRA Discovery Studies and planning phase. Key Personnel, Advisors and Service Providers engaged and secured

IP SECURED Provisional Patent, Patentability Study & Freedom to Operate

Note that this Infographic does not constitute an ‘Offer’ any investment will require formal and complete Offer Documentation to be acknowledged

Profile for BanksiaBioPharm

Banksia BioPharm Infographic  

Banksia BioPharm Infographic